GRAIL, Inc. is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms. As a startup it was a subsidiary of Illumina, which bought it outright in 2021. In June 2021 Galleri launched their liquid biopsy, or multi-cancer early detection test, which they called Galleri test. In 2023 EU regulators ordered Grail to be spun-out from Illumina which was completed on June 24, 2024.
Grail has received investment from 4 venture capital firms.
GRAIL, Inc. is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms.
Grail has received investment from 5AM Ventures, Amino Capital, Bezos Expeditions, Define Ventures. These venture capital firms and investors provide both capital and strategic support.
Grail was founded in 2015 and is headquartered in Menlo Park, California.
Grail operates in the Biotech sector. GRAIL, Inc. is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms.
